Skip to main content

Subbasal Nerve Plexus Alterations Following Ocular Proton Therapy in Uveal Melanoma Assessed by Corneal Confocal Microscopy

Journal
American journal of ophthalmology (Q1)
Published
1 October 2026
Study design
Prospective / inception cohort
Evidence level
Level 4, Very Low (CEBM 4)
Authors
Carlos Knappe, Claudia Prystupa, Zohreh Jami, Lynn S Zur Bonsen, Nathalie Biniaminov, Jens Heufelder, et al.
PMID
42822587
DOI
10.1016/j.ajo.2026.09.031

Why clinicians should know about it

  • Picked for Histology (top studies of the week, 4 October 2026): Subbasal nerve plexus after ocular proton therapy

Abstract

PURPOSE: To evaluate longitudinal changes in the subbasal nerve plexus (SNP) after ocular proton therapy (OPT) in eyes with uveal melanoma and associated changes in corneal sensitivity, cell density, and patient-reported outcomes. DESIGN: Prospective clinical cohort study. SUBJECTS: Fifty-eight patients (58 eyes) with uveal melanoma were enrolled; 54 had evaluable baseline corneal confocal microscopy images, and 40 formed the longitudinal analysis cohort. Follow-up data were available for 30 patients at 3 months and 27 patients at 12 months. METHODS: Corneal confocal microscopy was used to assess SNP parameters and cell density. Corneal sensitivity was measured with a Cochet-Bonnet aesthesiometer. Patient-reported outcomes were assessed using the German Ocular Surface Disease Index (OSDI) and selected domains from the German version of the NEI VFQ-25. Examinations were performed before OPT and at 3 and 12 months after OPT. MAIN OUTCOME MEASURES: Primary outcome measures were changes in corneal nerve fiber density (CNFD), corneal nerve branch density (CNBD), and corneal nerve fiber length (CNFL). Secondary outcome measures included corneal nerve fiber tortuosity (CNFT), cell density, corneal sensitivity, OSDI, and selected NEI VFQ-25 domains. RESULTS: CNFD decreased from 18.2 to 11.4 (3 months) and 12.7 no./mm² (12 months) (P = .002 and .001). CNBD decreased from 23.9 to 13.5 and 15.8 no./mm² (P = .012 and .040), and CNFL from 11.0 to 6.2 and 7.3 mm/mm² (both P < .001). Nerve loss was associated with treatment-related exposure, particularly the clinical target volume. CNFT decreased at 3 months (P = .018) and approached baseline at 12 months (P = .28). Corneal sensitivity did not change significantly. OSDI increased at 12 months (P = .049). After Benjamini-Hochberg correction, the 3-month CNFT, 12-month OSDI, and 12-month cell density changes were no longer significant. Among NEI VFQ-25 domains, only peripheral vision declined (84 to 68; P = .006). CONCLUSIONS: OPT was associated with marked reduction of SNP parameters, with only partial recovery by 12 months. Greater nerve loss was associated with larger treatment volumes and greater corneal irradiation. Cell density and corneal sensitivity remained unchanged, whereas patient-reported outcomes did not consistently reflect structural denervation.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.